LCT

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

Living Cell Technologies Limited

🇦🇺 ASX

👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

2
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as diabetes and Parkinson's disease. The company operates in both Australia and New Zealand, being the research and development and product development into living cell technologies. The firm's product candidate includes NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease. Choroid plexus cells are naturally occurring support cells for the brain and secrete cerebrospinal fluid (CSF), which contains a range of factors that support nerve cell functions and protective enzymes that are crucial for nerve growth and healthy functioning. In NTCELL, the porcine choroid plexus cells are coated with LCT's technology IMMUPEL to protect them from attack by the immune system. The firm has completed two clinical trials of NTCELL in Parkinson's disease.

📈 Performance

Price History

-69.19%

1M

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.01

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in LCT

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

48 weeks

💵 Average investment amount

$491

Last time a customer invested in LCT

952 days
LCT investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in LCT also invest in...

Algorae Pharmaceuticals Limited

1AI

Algorae Pharmaceuticals Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing novel treatments for medical conditions with under met medical needs. Its programs include AlgoraeOS, Dementia and Parkinson’s. Its drug candidates include NTCELL for Parkinson’s disease and the AI-116 combination drug candidate for dementia. AlgoraeOS is a closed-loop platform, leveraging advanced computational tools to generate novel insights in-silico that are being developed to initiate or accelerate therapeutic programs. The AI-116 is a novel combination drug candidate made up of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The NTCELL is an alginate coated capsule product containing clusters of neonatal porcine choroid plexus cells that are injected into the damaged site within the brain to target the treatment of Parkinson’s disease.

🙌 Performance (5Yr p.a)

-12.22%

📊 Share price

$0.01 AUD

🧬 BIOTECHNOLOGY

Find Out More

QAU.AX was created on 2011-05-03 by BetaShares. The fund's investment portfolio concentrates primarily on gold commodities. The investment objective of the Fund is to provide an investment return, before fees and expenses, that closely tracks the performance of the price of gold bullion, with a currency hedge against movements in the AUD/USD exchange rate.

🙌 Performance (5Yr p.a)

8.19%

📊 Share price

$21.44 AUD

📈 HIGH PRICE GROWTH

📞 COMMUNICATIONS

Argosy Minerals Ltd. develops and produces lithium, base metals, graphite, and related minerals. The company is headquartered in Perth, Western Australia. The firm has interest in the Rincon Lithium Project in Salta Province, Argentina and a 100% interest in the Tonopah Lithium Project in Nevada, United States. The Rincon Lithium Project comprises up to 2,794 hectares of Mining Titles and mining easement landholdings at the Salar del Rincon in Salta Province, Argentina. The Project is located in the elevated and arid Puna region of Argentina and forms part of a number of highly mineralized salars in production and development. The Company’s Tonopah Lithium Project is located within the Big Smokey Valley region in Nevada, United States, and comprises 425 claims covering an area of approximately 34.25 square kilometers (km2). The Tonopah Lithium Project is directly analogous to the neighboring Silver Peak Lithium Mine deposit model, both geologically and structurally.

🙌 Performance (5Yr p.a)

-9.25%

📊 Share price

$0.04 AUD

⛏️ MINING

Alara Resources Ltd. operates as a mineral exploration company. The company is headquartered in Balcatta, Western Australia. The company went IPO on 2007-05-24. Its projects include Al Wash-hi Majaza Copper-Gold Project, Daris Copper-Gold Project, Awtad Copper-Gold Project, Mullaq Copper-Gold Project and Al Ajal Copper-Gold Project. Its Al Hadeetha Wash-hi Majaza Copper-Gold Project is located over 160 kilometers (km) south-west of the capital city Muscat, in the Sultanate of Oman. Its Daris Project consists of two high-grade copper mineralization within the 587 square kilometers (km2) Block 7 Exploration License. Its Awtad Project comprises an area of approximately 497 km2 (Block 8) and is located immediately adjacent to the Block 7 (Daris Copper-Gold Project). Its Mullaq Exploration License area is adjacent to the Wash-hi Exploration License. Its Al Ajal Prospect is located near the village of Al Ajal in the Taww area, near the northern coast of the Sultanate of Oman and about 65 km west of Muscat.

🙌 Performance (5Yr p.a)

18.89%

📊 Share price

$0.04 AUD

⛏️ MINING

📈 HIGH PRICE GROWTH